Show simple item record

dc.contributor.authorXu, Jianwen
dc.contributor.authorLi, Xinning
dc.contributor.authorLian, Jane B.
dc.contributor.authorAyers, David C.
dc.contributor.authorSong, Jie
dc.date2022-08-11T08:10:08.000
dc.date.accessioned2022-08-23T16:56:52Z
dc.date.available2022-08-23T16:56:52Z
dc.date.issued2009-10-08
dc.date.submitted2011-05-26
dc.identifier.citationJ Orthop Res. 2009 Oct;27(10):1306-11. <a href="http://dx.doi.org/10.1002/jor.20890">Link to article on publisher's site</a>
dc.identifier.issn0736-0266 (Linking)
dc.identifier.doi10.1002/jor.20890
dc.identifier.pmid19350632
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43020
dc.description.abstractWe tested the hypothesis that synthetic composites containing a high percentage of osteoconductive biominerals well-integrated with a hydrophilic polymer matrix can be engineered to provide both the structural and biochemical framework of a viable synthetic bone substitute. FlexBone, an elastic hydrogel-mineral composite exhibiting excellent structural integration was prepared by crosslinking poly(2-hydroxyethyl methacrylate) hydrogel in the presence of 25 wt% nanocrystalline hydroxyapatite and 25 wt% tricalcium phosphate. Biologically active factors tetracycline, BMP-2/7, and RANKL that stimulate bone formation and remodeling were encapsulated into FlexBone during polymerization or via postpolymerization adsorption. SEM and dynamic mechanical analyses showed that the encapsulation of tetracycline (5.0 wt%) did not compromise the structural integrity and compressive behavior of FlexBone, which could withstand repetitive megapascal-compressive loadings and be securely press-fitted into critical femoral defects. Dose-dependent, sustained in vitro release of tetracycline was characterized by spectroscopy and bacterial inhibition. A single dose of 40 ng BMP-2/7 or 10 ng RANKL pre-encapsulated with 50 mg FlexBone, released over 1 week, was able to induce local osteogenic differentiation of myoblast C2C12 cells and osteoclastogenesis of macrophage RAW264.7 cells, respectively. With a bonelike structural composition, useful surgical handling characteristics, and tunable biochemical microenvironment, FlexBone provides an exciting opportunity for the treatment of hard-to-heal skeletal defects with minimal systemic side effects. Inc.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19350632&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/jor.20890
dc.subjectAnimals
dc.subjectBone Morphogenetic Protein 2
dc.subjectBone Morphogenetic Protein 7
dc.subjectBone Substitutes
dc.subjectCell Differentiation
dc.subjectCell Line
dc.subjectHumans
dc.subjectMacrophages
dc.subjectMice
dc.subjectMyoblasts, Skeletal
dc.subjectOsteoclasts
dc.subjectOsteogenesis
dc.subjectRANK Ligand
dc.subjectRecombinant Proteins
dc.subjectTetracycline
dc.subjectOrthopedics
dc.subjectRehabilitation and Therapy
dc.titleSustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute
dc.typeJournal Article
dc.source.journaltitleJournal of orthopaedic research : official publication of the Orthopaedic Research Society
dc.source.volume27
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/ortho_pp/28
dc.identifier.contextkey2032267
html.description.abstract<p>We tested the hypothesis that synthetic composites containing a high percentage of osteoconductive biominerals well-integrated with a hydrophilic polymer matrix can be engineered to provide both the structural and biochemical framework of a viable synthetic bone substitute. FlexBone, an elastic hydrogel-mineral composite exhibiting excellent structural integration was prepared by crosslinking poly(2-hydroxyethyl methacrylate) hydrogel in the presence of 25 wt% nanocrystalline hydroxyapatite and 25 wt% tricalcium phosphate. Biologically active factors tetracycline, BMP-2/7, and RANKL that stimulate bone formation and remodeling were encapsulated into FlexBone during polymerization or via postpolymerization adsorption. SEM and dynamic mechanical analyses showed that the encapsulation of tetracycline (5.0 wt%) did not compromise the structural integrity and compressive behavior of FlexBone, which could withstand repetitive megapascal-compressive loadings and be securely press-fitted into critical femoral defects. Dose-dependent, sustained in vitro release of tetracycline was characterized by spectroscopy and bacterial inhibition. A single dose of 40 ng BMP-2/7 or 10 ng RANKL pre-encapsulated with 50 mg FlexBone, released over 1 week, was able to induce local osteogenic differentiation of myoblast C2C12 cells and osteoclastogenesis of macrophage RAW264.7 cells, respectively. With a bonelike structural composition, useful surgical handling characteristics, and tunable biochemical microenvironment, FlexBone provides an exciting opportunity for the treatment of hard-to-heal skeletal defects with minimal systemic side effects. Inc.</p>
dc.identifier.submissionpathortho_pp/28
dc.contributor.departmentDepartment of Orthopedics and Physical Rehabilitation
dc.contributor.departmentDepartment of Cell Biology
dc.source.pages1306-11


This item appears in the following Collection(s)

Show simple item record